• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·BIOWKS.ST
Share

Bio-Works Technologies AB Stocks

SEK 3.17Last Updated 21.10.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

SEK 31.96M

SEK 3.17
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bio-Works Technologies AB (publ) is a biotechnology company that specializes in the research, development, production, and distribution of agarose-based separation products. These sophisticated solutions are designed to facilitate the purification of proteins, peptides, and other biomolecules, with a primary focus on the Swedish market. Their comprehensive product portfolio encompasses items such as activated and affinity resins, BabyBio columns, immobilized metal-ion affinity chromatography (IMAC) resins, ion exchange resins, OptioBio glass columns, screening kits, and size exclusion chromatography (SEC) resins. These offerings find use across various applications, including those concerning antibodies, His-tagged proteins, other proteins, peptides, oligonucleotides, and in the purification of viruses and vaccine development. Established in 2006, the company is headquartered in Uppsala, Sweden.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 00:20

Memory chip manufacturers' stocks are under pressure. Is it worth investing in them?

27.10.2026 22:38

GM will move its listing to the Nasdaq. What does this mean for its stock?

27.10.2026 21:09

Boeing shares plunge as 737 Max ramp-up delays overshadow top-line growth in 3Q

27.10.2026 19:50

‘Stoked greed a lot more than fear’: Anthropic IPO filing revives faith in AI stocks

27.10.2026 18:51

Mercedes No Longer Expects Profit Growth: Sales in China Plummeted by 30%

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026